| Literature DB >> 30756454 |
Julinton Sianturi1, Yoshiyuki Manabe1,2, Hao-Sheng Li1, Li-Ting Chiu3, Tsung-Che Chang1, Kento Tokunaga1, Kazuya Kabayama1,2, Masahiro Tanemura4, Shinji Takamatsu5, Eiji Miyoshi5, Shang-Cheng Hung3, Koichi Fukase1,2.
Abstract
Cancer treatment with antibodies (Abs) is one of the most successful therapeutic strategies for obtaining high selectivity. In this study, α-gal-Ab conjugates were developed that dramatically increased cellular cytotoxicity by recruiting natural Abs through the interaction between α-gal and anti-gal Abs. The potency of the α-gal-Ab conjugates depended on the amount of α-gal conjugated to the antibody: the larger the amount of α-gal introduced, the higher the level of cytotoxicity observed. The conjugation of antibodies with an α-gal dendrimer allowed the introduction of large amounts of α-gal to the Ab, without loss of affinity for the target cell. The method described here will enable the re-development of Abs to improve their potency.Entities:
Keywords: antibody-drug conjugates; dendrimer; immunotherapy; α-gal epitope
Year: 2019 PMID: 30756454 DOI: 10.1002/anie.201812914
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336